Leptin and Adiponectin as Immunohistochemical Biomarkers in Colorectal Cancer: Publication Trends and Research Advances
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background: Leptin and adiponectin play a key role in obesity-associated malignancy, particularly in colorectal cancer (CRC). Immunohistochemical (IHC) evaluation of these adipokines may offer valuable prognostic insights in CRC. This study aimed to analyze global publication trends and summarize current knowledge on the potential of these hormones as IHC biomarkers in CRC. Methods: A problem-oriented bibliometric analysis, including publications from 2000 to 2025, was performed across the MEDLINE and Scopus databases. In parallel, a literature review was conducted to present the biological and clinical relevance of these adipokines in CRC. Results and Discussion: A total of 101 publications were identified. Scopus indexed substantially more studies than MEDLINE. The journals Cancer Research, Journal of BUON, Cells, BMC Cancer, and Asian Pacific Journal of Cancer Prevention were identified as the core journals publishing on this topic over the 25-year period. The leading countries were China and the USA. A review of the literature showed that adiponectin is a promising prognostic marker, while leptin appears to be a better indicator of disease progression. Conclusions: IHC research on leptin and adiponectin in CRC is a promising but still underexplored area. Their integration with routine molecular assessment has the potential to improve patient stratification.